Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nevirapine
Drug ID BADD_D01557
Description A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Indications and Usage For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Marketing Status approved
ATC Code J05AG01
DrugBank ID DB00238
KEGG ID D00435
MeSH ID D019829
PubChem ID 4463
TTD Drug ID D0O2EM
NDC Product Code 53104-7546; 70159-002; 65862-027; 0378-4050; 64380-709; 65862-932; 65862-933; 31722-505; 65862-057; 68554-0044; 33342-004; 0597-0047; 64220-102; 0378-4890; 65162-209; 33342-238; 42571-131
UNII 99DK7FVK1H
Synonyms Nevirapine | Nevirapine Hemihydrate | Hemihydrate, Nevirapine | Viramune | BI-RG-587 | BI RG 587 | BIRG587
Chemical Information
Molecular Formula C15H14N4O
CAS Registry Number 129618-40-2
SMILES CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.002652%
Abdominal pain07.01.05.002--
Abortion spontaneous18.01.04.0010.005304%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.007956%Not Available
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase13.03.04.002--Not Available
Alanine aminotransferase abnormal13.03.04.003--Not Available
Alanine aminotransferase increased13.03.04.005--
Anaemia01.03.02.0010.006630%
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.003978%
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase13.03.04.008--Not Available
Aspartate aminotransferase abnormal13.03.04.009--Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood bilirubin13.03.04.015--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood triglycerides increased13.12.03.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Breast enlargement21.05.04.001--Not Available
Cardiac failure congestive02.05.01.0020.006630%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.0070.007956%
Cholestasis09.01.01.0010.003978%Not Available
Chronic hepatitis B09.01.09.008; 11.05.28.001--Not Available
Condition aggravated08.01.03.0040.005304%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene